Effect of different doses of Galcanezumab vs Placebo for episodic migraine prevention a randomized clinical trial

Vladimir Skljarevski, Tina M. Oakes, Qi Zhang, Margaret B. Ferguson, James Martinez, Angelo Camporeale, Kirk W. Johnson, Qiuling Shan, Jeffrey Carter, Aaron Schacht, Peter J. Goadsby, David William Dodick

Research output: Contribution to journalArticle

55 Citations (Scopus)

Abstract

IMPORTANCE Galcanezumab (LY2951742), a monoclonal antibody against calcitonin gene-related peptide (CGRP), is one of a novel class of new medicines for migraine prevention. OBJECTIVE To assess whether at least 1 dose of galcanezumab was superior to placebo for episodic migraine prevention. DESIGN, SETTING, AND PARTICIPANTS A randomized clinical trial was conducted in the United States (July 7, 2014, to August 19, 2015) in clinics of 37 licensed physicians with a specialty including, but not limited to, psychiatry, neurology, internal medicine, and primary care. Subcutaneous injections of galcanezumab, 5, 50, 120, or 300 mg, or placebo were given monthly during the 3-month treatment period. A total of 936 patients were assessed; 526 did not meet study entry or baseline criteria and 410 patients were randomly assigned to receive placebo or galcanezumab. Analyses were conducted on an intent-to-treat population, which included all patients who were randomized and received at least 1 dose of study drug. INTERVENTIONS Short-term migraine treatments were allowed as needed except for opioids or barbiturates. MAIN OUTCOMES AND MEASURES To determine if at least 1 of the 4 doses of galcanezumab tested was superior to placebo for migraine prevention measured by the mean change from baseline in the number of migraine headache days 9 weeks to 12 weeks after randomization. RESULTS Of the 936 patients assessed, 410 met entry criteria (aged 18-65 years with 4-14 migraine headache days per month and migraine onset prior to age 50 years) and were randomized to receive placebo or galcanezumab. For the primary end point, galcanezumab, 120 mg, significantly reduced migraine headache days compared with placebo (99.6% posterior probability −4.8 days; 90% BCI, −5.4 to −4.2 days vs 95% superiority threshold [Bayesian analysis] −3.7 days; 90% BCI, −4.1 to −3.2 days). Adverse events reported by 5% or more of patients in at least 1 galcanezumab dose group and more frequently than placebo included injection-site pain, upper respiratory tract infection, nasopharyngitis, dysmenorrhea, and nausea. CONCLUSIONS AND RELEVANCE Monthly subcutaneous injections of galcanezumab, both 120 mg and 300 mg, demonstrated efficacy (repeated-measures analysis) for the preventive treatment of migraine and support further development in larger phase 3 studies. All dosages were safe and well tolerated for the preventive treatment of episodic migraine.

Original languageEnglish (US)
Pages (from-to)187-193
Number of pages7
JournalJAMA Neurology
Volume75
Issue number2
DOIs
StatePublished - Feb 1 2018

Fingerprint

Migraine Disorders
Randomized Controlled Trials
Placebos
Subcutaneous Injections
Nasopharyngitis
Dysmenorrhea
Barbiturates
Bayes Theorem
Calcitonin Gene-Related Peptide
Therapeutics
Neurology
Internal Medicine
Random Allocation
Respiratory Tract Infections
Nausea
Opioid Analgesics
Psychiatry
Primary Health Care
Monoclonal Antibodies
Physicians

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Effect of different doses of Galcanezumab vs Placebo for episodic migraine prevention a randomized clinical trial. / Skljarevski, Vladimir; Oakes, Tina M.; Zhang, Qi; Ferguson, Margaret B.; Martinez, James; Camporeale, Angelo; Johnson, Kirk W.; Shan, Qiuling; Carter, Jeffrey; Schacht, Aaron; Goadsby, Peter J.; Dodick, David William.

In: JAMA Neurology, Vol. 75, No. 2, 01.02.2018, p. 187-193.

Research output: Contribution to journalArticle

Skljarevski, V, Oakes, TM, Zhang, Q, Ferguson, MB, Martinez, J, Camporeale, A, Johnson, KW, Shan, Q, Carter, J, Schacht, A, Goadsby, PJ & Dodick, DW 2018, 'Effect of different doses of Galcanezumab vs Placebo for episodic migraine prevention a randomized clinical trial', JAMA Neurology, vol. 75, no. 2, pp. 187-193. https://doi.org/10.1001/jamaneurol.2017.3859
Skljarevski, Vladimir ; Oakes, Tina M. ; Zhang, Qi ; Ferguson, Margaret B. ; Martinez, James ; Camporeale, Angelo ; Johnson, Kirk W. ; Shan, Qiuling ; Carter, Jeffrey ; Schacht, Aaron ; Goadsby, Peter J. ; Dodick, David William. / Effect of different doses of Galcanezumab vs Placebo for episodic migraine prevention a randomized clinical trial. In: JAMA Neurology. 2018 ; Vol. 75, No. 2. pp. 187-193.
@article{cdcf77cf4891451b93b3985353402f72,
title = "Effect of different doses of Galcanezumab vs Placebo for episodic migraine prevention a randomized clinical trial",
abstract = "IMPORTANCE Galcanezumab (LY2951742), a monoclonal antibody against calcitonin gene-related peptide (CGRP), is one of a novel class of new medicines for migraine prevention. OBJECTIVE To assess whether at least 1 dose of galcanezumab was superior to placebo for episodic migraine prevention. DESIGN, SETTING, AND PARTICIPANTS A randomized clinical trial was conducted in the United States (July 7, 2014, to August 19, 2015) in clinics of 37 licensed physicians with a specialty including, but not limited to, psychiatry, neurology, internal medicine, and primary care. Subcutaneous injections of galcanezumab, 5, 50, 120, or 300 mg, or placebo were given monthly during the 3-month treatment period. A total of 936 patients were assessed; 526 did not meet study entry or baseline criteria and 410 patients were randomly assigned to receive placebo or galcanezumab. Analyses were conducted on an intent-to-treat population, which included all patients who were randomized and received at least 1 dose of study drug. INTERVENTIONS Short-term migraine treatments were allowed as needed except for opioids or barbiturates. MAIN OUTCOMES AND MEASURES To determine if at least 1 of the 4 doses of galcanezumab tested was superior to placebo for migraine prevention measured by the mean change from baseline in the number of migraine headache days 9 weeks to 12 weeks after randomization. RESULTS Of the 936 patients assessed, 410 met entry criteria (aged 18-65 years with 4-14 migraine headache days per month and migraine onset prior to age 50 years) and were randomized to receive placebo or galcanezumab. For the primary end point, galcanezumab, 120 mg, significantly reduced migraine headache days compared with placebo (99.6{\%} posterior probability −4.8 days; 90{\%} BCI, −5.4 to −4.2 days vs 95{\%} superiority threshold [Bayesian analysis] −3.7 days; 90{\%} BCI, −4.1 to −3.2 days). Adverse events reported by 5{\%} or more of patients in at least 1 galcanezumab dose group and more frequently than placebo included injection-site pain, upper respiratory tract infection, nasopharyngitis, dysmenorrhea, and nausea. CONCLUSIONS AND RELEVANCE Monthly subcutaneous injections of galcanezumab, both 120 mg and 300 mg, demonstrated efficacy (repeated-measures analysis) for the preventive treatment of migraine and support further development in larger phase 3 studies. All dosages were safe and well tolerated for the preventive treatment of episodic migraine.",
author = "Vladimir Skljarevski and Oakes, {Tina M.} and Qi Zhang and Ferguson, {Margaret B.} and James Martinez and Angelo Camporeale and Johnson, {Kirk W.} and Qiuling Shan and Jeffrey Carter and Aaron Schacht and Goadsby, {Peter J.} and Dodick, {David William}",
year = "2018",
month = "2",
day = "1",
doi = "10.1001/jamaneurol.2017.3859",
language = "English (US)",
volume = "75",
pages = "187--193",
journal = "JAMA Neurology",
issn = "2168-6149",
publisher = "American Medical Association",
number = "2",

}

TY - JOUR

T1 - Effect of different doses of Galcanezumab vs Placebo for episodic migraine prevention a randomized clinical trial

AU - Skljarevski, Vladimir

AU - Oakes, Tina M.

AU - Zhang, Qi

AU - Ferguson, Margaret B.

AU - Martinez, James

AU - Camporeale, Angelo

AU - Johnson, Kirk W.

AU - Shan, Qiuling

AU - Carter, Jeffrey

AU - Schacht, Aaron

AU - Goadsby, Peter J.

AU - Dodick, David William

PY - 2018/2/1

Y1 - 2018/2/1

N2 - IMPORTANCE Galcanezumab (LY2951742), a monoclonal antibody against calcitonin gene-related peptide (CGRP), is one of a novel class of new medicines for migraine prevention. OBJECTIVE To assess whether at least 1 dose of galcanezumab was superior to placebo for episodic migraine prevention. DESIGN, SETTING, AND PARTICIPANTS A randomized clinical trial was conducted in the United States (July 7, 2014, to August 19, 2015) in clinics of 37 licensed physicians with a specialty including, but not limited to, psychiatry, neurology, internal medicine, and primary care. Subcutaneous injections of galcanezumab, 5, 50, 120, or 300 mg, or placebo were given monthly during the 3-month treatment period. A total of 936 patients were assessed; 526 did not meet study entry or baseline criteria and 410 patients were randomly assigned to receive placebo or galcanezumab. Analyses were conducted on an intent-to-treat population, which included all patients who were randomized and received at least 1 dose of study drug. INTERVENTIONS Short-term migraine treatments were allowed as needed except for opioids or barbiturates. MAIN OUTCOMES AND MEASURES To determine if at least 1 of the 4 doses of galcanezumab tested was superior to placebo for migraine prevention measured by the mean change from baseline in the number of migraine headache days 9 weeks to 12 weeks after randomization. RESULTS Of the 936 patients assessed, 410 met entry criteria (aged 18-65 years with 4-14 migraine headache days per month and migraine onset prior to age 50 years) and were randomized to receive placebo or galcanezumab. For the primary end point, galcanezumab, 120 mg, significantly reduced migraine headache days compared with placebo (99.6% posterior probability −4.8 days; 90% BCI, −5.4 to −4.2 days vs 95% superiority threshold [Bayesian analysis] −3.7 days; 90% BCI, −4.1 to −3.2 days). Adverse events reported by 5% or more of patients in at least 1 galcanezumab dose group and more frequently than placebo included injection-site pain, upper respiratory tract infection, nasopharyngitis, dysmenorrhea, and nausea. CONCLUSIONS AND RELEVANCE Monthly subcutaneous injections of galcanezumab, both 120 mg and 300 mg, demonstrated efficacy (repeated-measures analysis) for the preventive treatment of migraine and support further development in larger phase 3 studies. All dosages were safe and well tolerated for the preventive treatment of episodic migraine.

AB - IMPORTANCE Galcanezumab (LY2951742), a monoclonal antibody against calcitonin gene-related peptide (CGRP), is one of a novel class of new medicines for migraine prevention. OBJECTIVE To assess whether at least 1 dose of galcanezumab was superior to placebo for episodic migraine prevention. DESIGN, SETTING, AND PARTICIPANTS A randomized clinical trial was conducted in the United States (July 7, 2014, to August 19, 2015) in clinics of 37 licensed physicians with a specialty including, but not limited to, psychiatry, neurology, internal medicine, and primary care. Subcutaneous injections of galcanezumab, 5, 50, 120, or 300 mg, or placebo were given monthly during the 3-month treatment period. A total of 936 patients were assessed; 526 did not meet study entry or baseline criteria and 410 patients were randomly assigned to receive placebo or galcanezumab. Analyses were conducted on an intent-to-treat population, which included all patients who were randomized and received at least 1 dose of study drug. INTERVENTIONS Short-term migraine treatments were allowed as needed except for opioids or barbiturates. MAIN OUTCOMES AND MEASURES To determine if at least 1 of the 4 doses of galcanezumab tested was superior to placebo for migraine prevention measured by the mean change from baseline in the number of migraine headache days 9 weeks to 12 weeks after randomization. RESULTS Of the 936 patients assessed, 410 met entry criteria (aged 18-65 years with 4-14 migraine headache days per month and migraine onset prior to age 50 years) and were randomized to receive placebo or galcanezumab. For the primary end point, galcanezumab, 120 mg, significantly reduced migraine headache days compared with placebo (99.6% posterior probability −4.8 days; 90% BCI, −5.4 to −4.2 days vs 95% superiority threshold [Bayesian analysis] −3.7 days; 90% BCI, −4.1 to −3.2 days). Adverse events reported by 5% or more of patients in at least 1 galcanezumab dose group and more frequently than placebo included injection-site pain, upper respiratory tract infection, nasopharyngitis, dysmenorrhea, and nausea. CONCLUSIONS AND RELEVANCE Monthly subcutaneous injections of galcanezumab, both 120 mg and 300 mg, demonstrated efficacy (repeated-measures analysis) for the preventive treatment of migraine and support further development in larger phase 3 studies. All dosages were safe and well tolerated for the preventive treatment of episodic migraine.

UR - http://www.scopus.com/inward/record.url?scp=85041946321&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85041946321&partnerID=8YFLogxK

U2 - 10.1001/jamaneurol.2017.3859

DO - 10.1001/jamaneurol.2017.3859

M3 - Article

C2 - 29255900

AN - SCOPUS:85041946321

VL - 75

SP - 187

EP - 193

JO - JAMA Neurology

JF - JAMA Neurology

SN - 2168-6149

IS - 2

ER -